Letting cancer patients choose their Quit-Smoking method may boost success
NCT ID NCT04634071
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether letting cancer patients choose their own smoking cessation treatment helps them quit. 126 patients with tobacco-related cancers received either varenicline, bupropion, or nicotine patches based on their preference, plus counseling. The goal was to see if personalized choice improves quit rates compared to randomly assigned treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Varenicline, Bupropion, or nicotine patches
What this could lead to
If successful, this could show that letting cancer patients choose their own smoking cessation method helps them quit more effectively, potentially improving cancer treatment outcomes.
What could go wrong
This is a Phase 2 trial with only 126 participants, so results may not apply to all patients. Quitting smoking is difficult, and the study compares preferences, not a new drug, so the impact may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER, TREATMENT-RELATED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Med Center Health
Bowling Green, Kentucky, 42101, United States
-
Owensboro Health Mitchell Memorial Cancer Center
Owensboro, Kentucky, 42303, United States
-
University Of Kentucky, Markey Cancer Center
Lexington, Kentucky, 40536, United States